Dongbao Biotechnology: Baotou Dongbao Biotechnology Co., Ltd.’s announcement on the conversion of convertible corporate bonds in the first quarter of 2026
Securities code: 300239 Securities abbreviation: Dongbao Biologics Announcement number: 2026-021
Bond code: 123214 Bond abbreviation: Dongho Convertible Bonds
Baotou Dongbao Biotechnology Co., Ltd.
Announcement on the conversion of convertible corporate bonds in the first quarter of 2026
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special tips:
The conversion period of "Dongbao Convertible Bonds" (bond code: 123214) is from February 5, 2024 to July 30, 2029; the latest effective conversion price is 6.63 yuan/share.
In the first quarter of 2026, there was no equity conversion of "Dongbao Convertible Bonds".
As of the end of the first quarter of 2026, the company's remaining convertible bonds are 4,549,670, and the total remaining par amount is RMB 454,967,000.
In accordance with the relevant provisions of the "Shenzhen Stock Exchange GEM Stock Listing Rules" and the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 15 - Convertible Corporate Bonds", Baotou Dongbao Biotechnology Co., Ltd. (hereinafter referred to as the "Company" or "Dongbao Biotechnology") now announces the conversion of convertible corporate bonds and changes in the company's total share capital in the first quarter of 2026 as follows:
1. Issuance and listing of convertible corporate bonds
(1) Issuance of convertible bonds
With the approval of the "Reply on the Registration of Baotou Dongbao Biotechnology Co., Ltd.'s Issuance of Convertible Corporate Bonds to Unspecified Objects" issued by the China Securities Regulatory Commission (CSRC License No. 2023) 1517, the company issued 455,000,000 yuan of convertible corporate bonds that can be converted into the company's A shares to unspecified objects, with a face value of RMB 100 each, a total of 4,550,000 bonds. The total amount of funds raised by this issuance of convertible corporate bonds was RMB 455,000,000. After deducting the issuance expenses of RMB 12,736,600 (excluding tax), the actual net amount of funds raised was RMB 442,263,400. The above-mentioned raised funds have all been received on August 4, 2023. ShineWing Accounting Firm (Special General Partnership) has conducted capital verification on the receipt of funds raised from this issuance and issued the "Capital Verification Report on Funds Raised by Issuing Convertible Corporate Bonds to Unspecified Objects" No. "XYZH/2023JNAA1B0384".
(2) Listing status of convertible bonds
With the consent of the Shenzhen Stock Exchange, the company's convertible corporate bonds will be listed for trading on the Shenzhen Stock Exchange on August 18, 2023. The bond is referred to as "Dongbao Convertible Bonds" and the bond code is "123214".
(3) Conversion period of convertible bonds into shares
The conversion period of the convertible corporate bonds issued this time starts from the first trading day (February 5, 2024) six months after the completion of the issuance of the convertible corporate bonds (August 4, 2023) and ends on the maturity date of the convertible corporate bonds (July 30, 2029) (if it is a non-trading day, it will be postponed to the first trading day thereafter; no additional interest will be accrued on the interest payment during the postponement period). Holders of convertible bonds have the option to convert or not convert shares and become shareholders of the issuer on the next day of conversion.
(4) Adjustments to convertible bond conversion price
The initial conversion price of the company's convertible bonds is 6.67 yuan/share. The adjustment of convertible bond conversion price is as follows:
On May 31, 2024, the company completed the dividend payment for 2023. Based on the total share capital on the equity registration date (May 30, 2024), RMB 0.22 in cash (including tax) was distributed to all shareholders for every 10 shares. According to the "Baotou Dongbao Biotechnology Co., Ltd. Regarding the relevant provisions of the "Prospectus for the Issuance of Convertible Corporate Bonds to Unspecified Targets" on the adjustment of the conversion price of convertible corporate bonds, the conversion price of "Dongbao Convertible Bonds" was adjusted from 6.67 yuan/share to 6.65 yuan/share. The adjusted conversion price will take effect from May 31, 2024 (ex-rights and ex-dividend date). For details, please refer to the "Announcement on the Adjustment of the Conversion Price of "Dongbao Convertible Bonds" (Announcement Number: 2024-034).
On June 17, 2025, the company completed the dividend payment for 2024. Based on the total share capital on the equity registration date (June 16, 2025) minus the number of shares repurchased in the special securities account for repurchase, a cash dividend of RMB 0.25 (tax included) was distributed to all shareholders for every 10 shares. According to "Baotou East Dongbao Biotechnology Co., Ltd.'s Prospectus for Issuing Convertible Corporate Bonds to Unspecified Targets "Relevant provisions on the adjustment of the conversion price of convertible corporate bonds", the conversion price of "Dongbao Convertible Bonds" was adjusted from 6.65 yuan/share to 6.63 yuan/share, and the adjusted conversion price will take effect from June 17, 2025 (ex-rights and ex-dividend date). For details, please refer to the "Announcement on the Adjustment of the Conversion Price of "Dongbao Convertible Bonds" (Announcement Number: 2025-048).
2. "Dongbao Convertible Bonds" stock conversion and share changes
In the first quarter of 2026, "Dongbao Convertible Bonds" did not convert into shares and had no impact on the company's capital structure. As of March 31, 2026, there are still 4,549,670 "Dongbao Convertible Bonds", with a total remaining par amount of RMB 454,967,000. The company’s shares in the first quarter of 2026 are as follows:
As of December 31, 2025 As of March 31, 2026, the number of changes (shares)
Share situation Share situation
Nature of shares
Convertible bonds
Quantity (shares) Proportion (%) Others Subtotal Quantity (shares) Proportion (%)
Share transfer
1. Sales restriction conditions flow
3,846,150 0.65 0 0 0 3,846,150 0.65 tradable shares/non-tradable shares
Executive locked shares 3,846,150 0.65 0 0 0 3,846,150 0.65
2. Unlimited sales conditions
589,761,783 99.35 0 0 0 589,761,783 99.35 outstanding shares
- Total share capital 593,607,933 100.00 0 0 0 593,607,933 100.00
3. Other matters
If investors need to know other relevant content of "Dongbao Convertible Bonds", please read the full text of the "Prospectus for the Issuance of Convertible Corporate Bonds by Baotou Dongbao Biotechnology Co., Ltd. to Unspecified Targets" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on July 27, 2023.
If investors have any questions about the above content, please call the company’s investor consultation hotline: 0472-6208676.
4. Documents for reference
"Issuer's Equity Structure Table" issued by China Securities Depository and Clearing Co., Ltd. (Dongbao Biotechnology);
"Issuer's Equity Structure Table" (Dongbao Convertible Bonds) issued by China Securities Depository and Clearing Co., Ltd. Announcement is hereby made.
Board of Directors of Baotou Dongbao Biotechnology Co., Ltd.
April 1, 2026